Home Psoriasis Unichem Labs gets USFDA nod for plaque psoriasis drug

Unichem Labs gets USFDA nod for plaque psoriasis drug

71
0

Drug firm Unichem Laboratories on Friday said it has received approval from the US health regulator to market Apremilast tablets, used for treatment of plaque psoriasis.

Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Also read: Sun Pharma gains 2% on launching psoriasis drug in Japan

The company has received abbreviated new drug application (ANDA) approval to market its Apremilast tablets in the strengths of 10 mg, 20 mg and 30 mg from the United States Food and Drug Administration (USFDA), Unichem Labs said in a regulatory filing.

The approved product is a generic version of Amgen’s Otezla tablets.

Shares of Unichem Labs were trading 1.36 per cent higher at ₹309.75 apiece on the BSE.

https://www.thehindubusinessline.com/companies/unichem-labs-gets-usfda-nod-for-plaque-psoriasis-drug/article33878799.ece

This site uses Akismet to reduce spam. Learn how your comment data is processed.